Stock Ratings / Health Care / CVRX / earnings

NEPH (73) XTNT (69) TELA (36) DRIO (36) ⌘ Pro Terminal →

CVRx Inc. (CVRX) Next Earnings Date & Expected ±12.5% Move

Q: Is CVRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CVRx Inc. (NASDAQ: CVRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (+1.79% 1D, market cap $38.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CVRX ranks #556 in composite RQD confidence.

Q: How does CVRX compare to NEPH and XTNT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CVRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 85.3%, and ROIC of -35.0%. By comparison, NEPH (Nephros Inc.) holds a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M) and XTNT (Xtant Medical Holdings Inc.) posts a C+ grade (69/100 RQD, P/E N/A, ROIC 12.8%, cap $40.7M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for CVRX?

Per CVRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001235912), CVRx Inc. generated $56.7M in revenue (+10.4% YoY), -$53.3M in net income, and -$40.8M in free cash flow against $104.8M in total assets and $49.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is CVRX trading relative to its 50-day, 200-day, and 52-week technical levels?

CVRX last traded at $1.43 (+1.79% on volume of 257,051 shares), positioning the stock -36.73% below its 50-day simple moving average ($2.26) and -72.92% below its 200-day simple moving average ($5.28). Across its 52-week range of $1.25 to $11.30, CVRX sits at the 1.8% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).

Q: When is CVRX's next earnings date?

Based on SEC filing cadence, CVRx Inc. (CVRX)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is CVRX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CVRX, spanning a range between $1.25 and $1.61.

$1.43 +1.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.43

CVRx Inc. (CVRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $38.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.43 (+0.13%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CVRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY CVRX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.9 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.58-17.7% Next Q

Q2 (-2Q)

Grade D$1.30+9.2% Next Q

Q3 (-1Q)

Grade D$1.42+0.7% Next Q

Current

Grade D-$1.43-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CVRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CVRX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.50) forces dealer call-delta covering toward $11.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CVRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CVRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.18 Expected Swing

MODEL EARNINGS SETUP GAUGE

CVRX Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 10.4%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$56.7M	-$53.3M	-$40.8M	85.3%
FY 2024	2024-12-31	$51.3M	-$60.0M	-$40.5M	83.8%
FY 2023	2023-12-31	$39.3M	-$41.2M	-$39.0M	85.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CVRX)

✓Walkthrough of CVRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CVRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.96%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.41H $1.46L $1.38C $1.43VOL 272.7K

RES: $4.02SUP: $1.05SMA50: $2.26SMA200: $5.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CVRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CVRX Butterfly Map → + Track CVRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CVRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CVRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CVRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CVRX)

Health Care Rank #556 of 1016 ⚔️ NEPH vs CVRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CVRX vs. NEPH, XTNT, TELA, DRIO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CVRx Inc. (CVRX) ranks #556 by composite RQD confidence (43/100, grade D-) and #782 by equity capitalization ($38.0M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with CVRX at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CVRX ACTIVE CVRx Inc.	D-	43/100	—	85.3%	-35.0%	+1.79%	$38.0M	Benchmark Subject
NEPH Nephros Inc.	B	73/100	29.8x	61.9%	18.9%	+3.16%	$35.5M	/neph-vs-cvrx →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-cvrx →
TELA TELA Bio Inc.	D-	36/100	—	67.7%	-35.0%	-5.74%	$41.5M	/tela-vs-cvrx →
DRIO DarioHealth Corp.	D-	36/100	—	56.6%	-35.0%	-2.93%	$32.4M	/drio-vs-cvrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001235912

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CVRx Inc. (CVRX) reported GAAP revenue of $56.7M (+10.4% vs. FY2024 revenue of $51.3M , and +44.2% cumulative change since FY2023) , GAAP net income of -$53.3M, operating cash flow of -$40.2M, and free cash flow of -$40.8M (-0.6% YoY). On the balance sheet, CVRX closed FY2025 with $104.8M in total assets against $49.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$56.7M	-$53.3M	-$40.2M	-$40.8M	$104.8M	$49.5M
FY2024 (FY)	2024-12-31	$51.3M	-$60.0M	-$39.1M	-$40.5M	$133.4M	$49.3M
FY2023 (FY)	2023-12-31	$39.3M	-$41.2M	-$39.0M	-$39.0M	—	—

3. CVRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CVRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CVRx Inc. (NASDAQ: CVRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (+1.79% 1D, market cap $38.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CVRX ranks #556 in composite RQD confidence.

How does CVRX compare to NEPH and XTNT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CVRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 85.3%, and ROIC of -35.0%. By comparison, NEPH (Nephros Inc.) holds a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M) and XTNT (Xtant Medical Holdings Inc.) posts a C+ grade (69/100 RQD, P/E N/A, ROIC 12.8%, cap $40.7M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CVRX?

Per CVRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001235912), CVRx Inc. generated $56.7M in revenue (+10.4% YoY), -$53.3M in net income, and -$40.8M in free cash flow against $104.8M in total assets and $49.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CVRX trading relative to its 50-day, 200-day, and 52-week technical levels?

CVRX last traded at $1.43 (+1.79% on volume of 257,051 shares), positioning the stock -36.73% below its 50-day simple moving average ($2.26) and -72.92% below its 200-day simple moving average ($5.28). Across its 52-week range of $1.25 to $11.30, CVRX sits at the 1.8% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).

CVRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CVRX's next earnings date?

Based on SEC filing cadence, CVRx Inc. (CVRX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CVRX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CVRX, spanning a range between $1.25 and $1.61.

Direct Sub-Reports: CVRX RQD Cockpit CVRX 12M Forecast CVRX Earnings & Move CVRX Dividends & DRIP CVRX Insiders & 13F CVRX Whale Options CVRX Profit Sankey CVRX News & Why